Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maraviroc in Hospitalized COVID-19 Patients
NCT04441385Phase 2Terminated
- Sponsor
- Hospital Universitario Infanta Leonor
- Start
- Jun 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of maraviroc in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Hospital Universitario Infanta Leonor. Primary endpoint: Proportion of patients developing severe ARDS at 28 days. Started Jun 2020; status: terminated.
02
Drugs
maraviroc
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04441385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04441385.